A PYMNTS Company

EU: EC Greenlights Sanofi-Boehringer $20-billion asset swap

By  |  August 4, 2016

French drugmaker Sanofi secured EU antitrust approval on Thursday for its proposed buy of German peer Boehringer Ingelheim’s consumer health business after agreeing to divest businesses from both companies in nine EU countries.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Sanofi’s bid for Boehringer’s consumer health unit with an enterprise value of 6.7 bn is part of a $20-billion asset swap, with the German company taking over its animal health arm.

    The European Commission said the pledge to sell units in the Czech Republic, Estonia, France, Hungary, Greece, Ireland, Latvia, Poland and Slovakia addressed its concerns about higher prices for medicines.

    Full Content: The Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.